Company Encyclopedia
View More
name
Opthea Limited
OPT.AU
News
View More

Opthea Limited held its Annual General Meeting

Opthea Limited held its Annual General Meeting on November 11, 2025, where shareholders approved the re-election of Dr. Jeremy Levin and Ms. Kathy Connell as directors. Additionally, proposals for issuing options to Mr. Lawrence Gozlan and Ms. Kathy Connell under the NED Plan, as well as options to Dr. Jeremy Levin under the LTIP, were also approved.

Reuters·
US
OPT
0.00%
Reuters·
US
OPT
0.00%

Opthea to Delist from Nasdaq, Focuses on ASX and Australian Market

Opthea Limited (AU:OPT) has announced its voluntary delisting from the Nasdaq Stock Market, while retaining its listing on the Australian Securities Exchange (ASX). This decision aims to streamline operations and reduce costs, focusing on the Australian market to enhance shareholder value. The company will continue its American Depositary Receipt program for U.S. investors in the OTC market. The latest analyst rating for Opthea stock is a Sell, with a price target of A$0.05. Current market cap stands at A$738.8M.

Tip Ranks·
US
OPT
0.00%
Tip Ranks·
US
OPT
0.00%

Opthea (NASDAQ:OPT) Trading 7.2% Higher - Here's What Happened

Opthea Limited (NASDAQ:OPT) shares rose 7.2% to $3.41 on Friday, up from a previous close of $3.18. Analyst ratings show one Strong Buy, four Hold, and two Sell ratings, with a consensus target price of $1.33. Institutional investors own 55.95% of the stock, with significant increases in holdings from several firms. Opthea focuses on developing therapies for eye diseases in Australia, leveraging its intellectual property on Vascular Endothelial Growth Factors (VEGF).

Market Beat·
US
OPT
0.00%
Market Beat·
US
OPT
0.00%

Opthea Limited Schedules Virtual Annual General Meeting for November 2025

Opthea Limited has scheduled its virtual Annual General Meeting for November 11, 2025. Key agenda items include the re-election of directors and the adoption of the remuneration report. The latest analyst rating for OPT stock is a Hold with a $1.00 price target, while Spark's AI Analyst rates it as Underperform due to financial challenges. The stock shows a bearish trend, with unfavorable valuation metrics and a high beta, indicating a need for strategic improvements. Opthea focuses on developing therapies for eye diseases, with a current market cap of $485.2M.

Tip Ranks·
US
OPT
0.00%
Tip Ranks·
US
OPT
0.00%

Opthea Limited announces date for annual general meeting

Opthea Limited will hold its annual general meeting virtually on November 11, 2025. Shareholders will vote on the re-election of Dr. Jeremy Levin and Ms. Kathy Connell as directors, the adoption of the remuneration report, and the issuance of options to Mr. Lawrence Gozlan, Ms. Kathy Connell, and Dr. Jeremy Levin under respective plans.

Reuters·
US
OPT
0.00%
Reuters·
US
OPT
0.00%